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Summary
Type I interferons (IFNs) are a family of cytokines spe-
cialized to coordinate immunity to viruses and other
intracellular infections. In the past several years,
many of the receptors and signaling pathways that
link pathogen detection to induction of type I IFNs
have been identified and characterized. An integrated
picture has emerged in which type I IFNs have essen-
tial functions in several seemingly disparate pro-
cesses: they restrict viral spread by engaging machin-
ery that ultimately cripples and kills infected cells, yet
they are also positively linked to the activation and ex-
pansion of lymphocytes that are important for control
of intracellular infections. These advances highlight
the context-specific actions of type I IFNs and clarify
the multiple points at which they are integrated into
both innate and adaptive immunity.
Introduction
Viruses are the most abundant and diverse pathogens
on earth. One look at the genome of any organism con-
firms that viruses have been around for a very long time.
It is estimated that up to 40% of the human genome is
derived from fragments of ancestral viral sequence, and
approximately 1% of the genome consists of intact
endogenous retroviruses (Sverdlov, 2000). The impact of
viruses on our genes cannot be overstated: viruses are
likely responsible for generating much of the variation
that fueled selection of new traits and the evolution of
our species, including exon shuffling, gene duplication,
and diversification of noncoding regulatory elements.
Viruses can also be formidable pathogens and pose
a unique challenge for the host’s detection systems. It
is now well established that immune recognition focuses
on highly conserved, invariant structures of microbes
that are distinct from the host (Janeway, 1989). Unlike
bacteria and fungi, which contain easily distinguishable
microbe-specific structures, viruses are made entirely of
host-derived components. With no microbe-specific
‘‘pattern’’ to latch onto, the receptors that detect viruses
have instead evolved to recognize the one feature that is
shared without exception among all viruses: a genome
composed of nucleic acids. Importantly, nucleic acid
recognition is in principle an imperfect way for cells to
distinguish self from non-self for obvious reasons, yet
most (if not all) ways for a cell to signal the presence of
viral infection are based on it. The receptors that accom-
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nucleic acids in the midst of an abundance of host-
derived RNA and DNA. Because there is little structural
basis for discrimination between viral and host nucleic
acids, it appears that pattern recognition in this case is
aided by the compartmentalization of antiviral sensors
and by activities of host nucleases that help eliminate
self nucleic acids from the extracellular fluids and from
lysosomes (Barton et al., 2006; Napirei et al., 2000; Yosh-
ida et al., 2005). Additional mechanisms that help such
discrimination undoubtedly exist and await elucidation;
insight into this fundamental question is attainable now
that we know the identity of many of the receptors
involved, as discussed below.
All organisms are susceptible to viral infections and all
have a dedicated system to detect and prevent nucleic
acid parasitism. These systems range from restriction
enzymes and antiphage defense in prokaryotes to
the multilayered and complex networks of antiviral re-
sponses in higher metazoans. Each of these systems
directs responses that vary according to the organism’s
physiology and needs. Jawed vertebrates, which
evolved an adaptive immune system of T and B cells,
also developed the type I interferon (IFN) cytokine family
that is dedicated to signaling the presence of intracellu-
lar infection and facilitating communication among the
cells that provide defense against viruses and intracellu-
lar bacteria. All vertebrates examined to date have
a gene that encodes IFN-b and at least two that encode
IFN-a, together with natural killer (NK) cells, T cells, and
B cells; there is no known organism that has one of these
components without all of the others. The preservation
of type I IFNs throughout the vertebrate lineage sug-
gests an intimate functional linkage to adaptive immunity
that has become increasingly apparent with recent
experimental insights.
In this review, we will discuss the major receptor sys-
tems that detect viral infection and activate type I IFNs in
vertebrates, with an emphasis on how these systems
complement each other in host defense. We will attempt
to integrate important recent developments into the
well-established framework of IFN function that is dis-
cussed in the accompanying reviews (Honda et al.,
2006; van Boxel-Dezaire et al., 2006; Banchereau and
Pascual, 2006) and other papers (Honda et al., 2005b;
Garcia-Sastre and Biron, 2006; Levy et al., 2003; Stark
et al., 1998). These exciting advances clarify the mecha-
nisms by which IFNs are activated, provide insight into
their multiple and context-specific roles in antiviral
immunity, and may suggest new directions for therapeu-
tics and vaccine development.
Two Pathways for Type I IFN Induction:
Toll-like Receptors
Prior to the year 2000, no mammalian receptors that
linked viral recognition to activation of type I IFNs had
been identified. After several years of remarkable prog-
ress, it is now clear that two complementary receptor
systems account for most virus detection. A general
principle that has emerged is that all of these receptors
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into two categories: one class of receptors (exemplified
by RIG-I and MDA5 proteins) is expressed ubiquitously
and is localized to the cell’s cytosol where it detects viral
nucleic acids produced upon infection. The second class
of receptors (members of the Toll-like receptor [TLR]
family) detects viral nucleic acids in endosomes and
only in specialized cell types. This latter mode of recog-
nition does not require that the IFN-producing cells are
infected themselves and hence need not be ubiquitous.
The Toll-like receptors (TLRs) have been the subject
of intense investigation as prototypical signaling recep-
tors that activate immunity in response to microbial
stimuli (Akira et al., 2006; Iwasaki and Medzhitov,
2004). Several of the mammalian TLRs recognize differ-
ent types of nucleic acids, and together they provide
enough coverage to detect most types of viruses.
TLR3 recognizes double-stranded RNA, a common fea-
ture of both DNA and RNA viruses that until recently was
thought to be the principal (or even only) form of viral nu-
cleic acid recognized by the immune system (Alexopou-
lou et al., 2001). TLR7 and TLR8 detect single-stranded
RNA (ssRNA) and viruses that contain ssRNA genomes
(Diebold et al., 2004; Heil et al., 2004; Lund et al.,
2004). TLR9 detects unmethylated CpG motifs in DNA
that are common in DNA viruses and also bacteria
(Hemmi et al., 2000; Krug et al., 2004b; Lund et al., 2003).
The only known exception to the rule that all receptors
that activate type I IFNs detect nucleic acids is TLR4,
which detects lipopolysaccharides (LPS) derived from
gram-negative bacteria and activates type I IFNs in con-
ventional dendritic cells (DCs) and macrophages
through a signaling pathway that utilizes the adaptor
protein Trif (Oshiumi et al., 2003; Yamamoto et al.,
2002). It is completely unclear at present why the
TLR4-Trif pathway links recognition of bacterial cell
walls to cytokines that generally signal the presence of
a viral infection. By comparison, TLR2 also recognizes
cell wall components (peptidoglycans) but does not ac-
tivate IFNs (Takeuchi et al., 1999; Yang et al., 1998). It is
likely that the TLR4-Trif axis arose to harness some of
the functions of IFNs in enhancing T cell differentiation
and NK cell function, as discussed below.
TLRs are primarily expressed on key sentinel cells of
the innate immune system: macrophages and dendritic
cells (DCs). TLR3 is expressed by conventional DCs,
whereas TLRs 7 and 9 are expressed by both conven-
tional and plasmacytoid dendritic cells (pDCs). pDCs
have a specialized signaling pathway that links activa-
tion of TLRs 7 and 9 to the production of copious
amounts of type I IFNs, and they are primarily responsi-
ble for the systemic concentrations of IFNs detected
during many experimental viral infections (Colonna
et al., 2004; Krug et al., 2004a). One feature shared by
the four TLRs that sense nucleic acids is their intracellu-
lar localization: unlike all other TLRs, which are located
at the cell surface, TLRs 3, 7, and 9 signal from within
an acidified endosomal compartment. Consequently, in-
hibitors of endosomal acidification block the function of
these three TLRs but none of the others (Hacker et al.,
1998; Heil et al., 2003; Lee et al., 2006). This intracellular
localization is important for the ability of these TLRs to
discriminate between self and non-self nucleic acids: re-
locating TLR9 to the cell surface abolishes its ability torespond to virus-encapsulated DNA but enables recog-
nition of self-derived genomic DNA in the extracellular
milieu (Barton et al., 2006).
A key feature of TLR-dependent nucleic acid recogni-
tion is directly tied to their intracellular location: TLRs
sample material entering cells from the outside and
thus do not detect the presence of infection from within.
This material often consists of viral particles that be-
come uncoated or degraded upon endosomal acidifica-
tion, thus exposing their nucleic acids for recognition.
Recent evidence indicates that TLR3 also samples
apoptotic cells for viral dsRNA as they are engulfed
and degraded in the phagosome (Schulz et al., 2005).
Considering the strong link between viral infection and
apoptosis in vertebrates and the role of TLRs in antigen
presentation, this mechanism would provide an efficient
means for viral antigens within dead cells derived from
any tissue to be presented to T cells by uninfected
DCs, a process known as crosspresentation. The sepa-
ration of viral infection from viral recognition in DCs has
another important consequence: most viruses encode
proteins that potently antagonize type I IFN expression
and signaling within infected cells, but uninfected DCs
would be refractory to such inhibition.
Two Pathways for Type I IFN Induction:
Cytosolic Receptors
Although some TLRs can activate IFNs in a subset of
specialized cells, almost all nucleated cells respond to
viral infection by producing type I IFNs. Fujita and col-
leagues advanced our understanding of this more
broadly expressed virus-detection system by identifying
the caspase recruitment domain (CARD)-containing
RNA helicases retinoic acid inducible gene-I (RIG-I)
and melanoma differentiation antigen 5 (MDA5) as sen-
sors that link detection of dsRNA to activation of type I
IFNs (Yoneyama et al., 2004). Both RIG-I and MDA5
use the CARD-containing adaptor protein MAVS (also
known as IPS-1, VISA, or CARDIF) to activate the IFN-
b gene (Kawai et al., 2005; Meylan et al., 2005; Seth
et al., 2005; Xu et al., 2005). The details of the RNA-
activated signaling pathways have been reviewed else-
where (Kawai and Akira, 2006; McWhirter et al., 2005),
and recent developments will also be discussed in the
accompanying review (Honda et al., 2006).
Knockout mice lacking RIG-I and MDA5 have dramatic
phenotypes when challenged with RNA viruses in vitro
and in vivo. RIG-I-deficient cells fail to activate type I
IFN production when challenged with several classes
of viruses, including vesicular stomatitis virus (VSV),
Newcastle disease virus, Sendai virus, influenza virus,
and Japanese encephalitis virus (Kato et al., 2005,
2006). Interestingly, pDC-derived type I IFN production
in response to these viruses requires MyD88-dependent
TLR signaling but not RIG-I, highlighting the fact that
TLRs and cytosolic sensors can independently activate
type I IFNs in vivo (Kato et al., 2005). MDA5 is the primary
cytosolic receptor for the RNA polymer poly I:C and is
required for detection of the picornavirus encephalo-
myocarditis virus (EMCV) (Gitlin et al., 2006; Kato et al.,
2006). Together, these studies establish that RIG-I and
MDA5 detect different viral RNA structures, although
the precise nature of these structuresand the biochemical
basis for this differential recognition remains unknown.
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that both RIG-I and MDA5 use this adaptor protein to ac-
tivate type I IFNs (Kumar et al., 2006; Sun et al., 2006).
Consequently, the phenotype of MAVS-deficient mice
resembles the sum of RIG-I and MDA5 deficiency
when challenged with RNA viruses that are detected
by these helicases. Importantly, MAVS-deficient mice
are highly susceptible to infection with these viruses de-
spite an intact TLR-dependent recognition system. This
interesting observation formally demonstrates that al-
though the two receptor systems can independently ac-
tivate the type I IFN response, they are not functionally
redundant. As discussed below, this also implies that
type I IFNs are not sufficient for antiviral defense and
that these cytosolic receptors may also control essential
antiviral functions in an IFN-independent manner.
In addition to intracellular recognition of viral dsRNA,
which has been known to exist for many years, foreign
DNA is also recognized by an intracellular sensor that
triggers type I IFN production (Ishii et al., 2006; Okabe
et al., 2005; Stetson and Medzhitov, 2006). This DNA-
recognition system presumably evolved to detect DNA
derived from DNA viruses during infection. Thus, similar
to RIG-I and MDA5, DNA recognition is a cell-autono-
mous and, presumably ubiquitous virus-recognition
system. The sensor for intracellular viral DNA is currently
unknown. Interestingly, however, the signaling pathway
induced by this sensor is distinct from RIG-I and MDA5
signaling in that it does not result in activation of NF-kB
transcription factor or MAP kinases, but does require
IRF3 for the induction of interferon genes (Stetson and
Medzhitov, 2006). Consistent with the different down-
stream signaling pathway, DNA-induced interferon pro-
duction is MAVS independent (Kumar et al., 2006; Sun
et al., 2006). The reason why dsRNA and DNA trigger dif-
ferent signaling pathways presumably has to do with the
induction of distinct effector responses to RNA and DNA
viruses. These two types of viruses differ dramatically
with regards to their size and infection strategies, and
so it is not surprising that different antiviral responses
need to be induced to interfere with stages of the infec-
tion cycle unique to RNA or DNA viruses.
Interestingly, a potent type I interferon response is
also induced by several intracellular bacterial infections.
This has been most clearly demonstrated in the case of
Listeria monocytogenes (O’Riordan et al., 2002),
although other intracellular bacteria like Shigella flexneri
and Legionella pneumophila induce interferon re-
sponses as well (Hess et al., 1987; Stetson and Medzhi-
tov, 2006). It appears that the induction of IFN-b in
Listeria-infected macrophages may be mediated by
the DNA-recognition pathway (Stetson and Medzhitov,
2006). Consistent with this possibility, IFN-b induction
by Listeria is TLR and nucleotide binding oligomeriza-
tion domain (NOD) protein independent, but requires in-
vasion of the host cell’s cytosol (O’Connell et al., 2005;
O’Riordan et al., 2002; Stockinger et al., 2004). In the
case of Listeria, IFN-b production and type I IFN-
activated signaling in lymphocytes makes the host
more susceptible to infection (Auerbuch et al., 2004;
Carrero et al., 2004, 2006; O’Connell et al., 2004). It is im-
portant to note that although type I IFNs appear to be
detrimental to the host during Listeria infection, they
are likely only one facet of the response activated bythe sensor(s) that detect cytosolic Listeria; this pathway
probably induces other cytokines and effector mecha-
nisms, some of which might be beneficial to the host.
Nonetheless, this finding is a dramatic example of con-
text-dependent effects of type I IFNs in the course of
infection, which appears to be a common theme in IFN
biology, as discussed below. In the case of other bacte-
ria that invade the host cytosol, it remains to be seen
whether IFNs have a protective or detrimental effect at
different stages of infection.
In summary, two distinct IFN-inducing systems are
now known to exist: one is restricted to endosomes of
specialized sentinel cells and mediated by TLRs, and
the other is a ubiquitous cytosolic viral detection system
mediated by RIG-I and MDA5 and a DNA sensor(s). In
principle, any type of virus would be vulnerable to detec-
tion by both a TLR and a cytosolic sensor; this breadth of
coverage is remarkable considering the staggering
diversity of viruses and the comparably tiny number of
receptors charged with sensing them. It would be inter-
esting to determine whether retroviruses, which gener-
ate both RNA and DNA during their infectious cycle,
are detected by sensors of both of these nucleic acids
or whether one type of receptor predominates. Based
on the recent insights into the receptor systems that
sense nucleic acids and the generation of knockout
mice lacking specific components of each pathway,
we are now able to evaluate the relative contributions
of each of these systems to antiviral immunity. What is
beginning to emerge from these studies is a more inte-
grated picture of the different ways in which type I
IFNs facilitate antiviral defense through both cell-intrin-
sic and non-cell-autonomous mechanisms.
Cell-Intrinsic Antiviral Defense: The ‘‘Antiviral State’’
The activity of type I IFNs was originally described al-
most 50 years ago as a soluble factor produced by cells
treated with inactivated, nonreplicating viruses that
blocked subsequent infection with live virus (Isaacs
and Lindenmann, 1957; Isaacs et al., 1957; Nagano
and Kojima, 1958). Interestingly, one group used the
RNA influenza virus whereas the other used the DNA
vaccinia virus, implying the existence of cellular sensors
of both types of viral nucleic acids even in the first re-
ports describing type I IFNs. As indicated in these initial
studies, type I IFNs produced by infected cells act in an
autocrine and paracrine manner to signal the presence
of viral infection. By signaling through the type I IFN
receptor, IFNs activate the inducible expression of
hundreds of genes that together establish the ‘‘antiviral
state’’ (van Boxel-Dezaire et al., 2006; Stark et al., 1998).
Antiviral state is a generic term and perhaps belies the
fact that we still have only an elementary understanding
of what exactly it is. Indeed, there are entire families of
IFN-inducible genes with completely unknown function,
including several large GTPases and a series of proteins
with tetratricopeptide repeat domains (IFITs) (Samuel,
2001). Although the function of each of these and other
IFN-inducible genes awaits elucidation, it is safe to
say that they act to cripple every stage of the viral life
cycle. Some IFN-inducible proteins have broad antiviral
effects. For example, 20-50 oligoadenylate synthases
(OAS) are activated by viral dsRNA and produce 20-50 oli-
goadenylates, which in turn activate the latent nuclease,
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376RNase L, resulting in the degradation of viral RNA tran-
scripts as well as host RNAs (Stark et al., 1998). Another
well-studied IFN-induced antiviral effector is PKR,
a member of the eukaryotic initiation factor 2a (eIF2a) ki-
nase family. Activation of PKR by dsRNA leads to eIF2a
phosphorylation with a consequent blockade of transla-
tion of most cellular and viral mRNAs. Interestingly,
translation of mRNAs containing upstream open reading
frames in their 50 UTRs is enhanced upon eIF2a phso-
phorylation. Most known examples of proteins encoded
by such mRNAs are restricted to the unfolded protein re-
sponse and nutrient deprivation or stress conditions
that activate other members of the eIF2a kinase family
(Harding et al., 2002). Conceivably, these proteins may
indirectly contribute to the antiviral state. However,
one would expect that some of the bona fide antiviral
effectors, including perhaps type I IFNs themselves,
may also be translated preferentially when PKR is acti-
vated and eIF2a phosphorylated.
In addition to the relatively nonspecific antiviral activ-
ities of PKR and OAS-RNaseL systems, certain IFN-
inducible genes may also exhibit specificity for distinct
classes of viruses as implied by the existence of distinct
sensors and signaling pathways that detect DNA or RNA
within infected cells. Recent studies demonstrate that
there are indeed IFN-inducible genes that are able to in-
tercept specific types of viruses. The MX and guanylate
binding proteins are large, IFN-inducible GTPases of the
dynamin family. The MX proteins have been shown to
have a protective effect against two RNA viruses, influ-
enza and VSV (Arnheiter et al., 1990; Pavlovic et al.,
1993). Although detailed mechanisms of MX and GBP
functions await elucidation, their structural similarity
with dynamin suggests that these proteins may interfere
with viral assembly and trafficking in the cell.
Perhaps the best example of virus-specific functions
of IFN-inducible genes and the most promising recent
development in the search for novel HIV therapeutics
is the recently discovered APOBEC3 family of cytidine
deaminases. It was established several years ago that
HIV deficient in the virion infectivity factor (vif) is only
able to form infectious viral particles in certain cell lines
(termed permissive) and not in human T cells and several
other cell lines (termed nonpermissive) (Fisher et al.,
1987; Gabuzda et al., 1992). The phenotype of the non-
permissive cells was interesting: they supported a single
round of virus production, but the newly formed virions
were unable to infect even permissive cells. Fusion of
permissive and nonpermissive cells established that
the nonpermissive phenotype was dominant and sug-
gested that a cellular factor expressed only in nonper-
missive cells could suppress infectivity of vif-deficient
HIV (Madani and Kabat, 1998). Malim and colleagues
used subtractive cDNA analysis to identify CEM15
(also known as APOBEC3G) as this factor and showed
that it is incorporated into vif-deficient, but not wild-
type, virions (Sheehy et al., 2002). Virion-incorporated
APOBEC3G deaminates cytosine to uracil in reverse-
transcribed retroviral DNA, generating catastrophic mu-
tations and rendering viral DNA susceptible to cleavage
by uracil DNA glycosylase and apurinic-apyrimidinic
(AP) endonuclease enzymes (Harris et al., 2003; Man-
geat et al., 2003). Interestingly, the deaminase activity
of APOBEC3G is not required for its antiretroviralfunction (Newman et al., 2005), and cellular (non-virus-
incorporated) APOBEC3G potently blocks vif+ HIV infec-
tion in resting CD4+ T cells (Chiu et al., 2005), suggesting
that the regulation of APOBEC3G function may be more
complex than initially suggested. Nonetheless, these
findings provide a remarkable example of IFN-inducible
genes targeting a specific class of viruses.
Although the effector proteins induced by type I IFNs
are clearly an essential component of the antiviral state,
mounting evidence suggests that these cannot mediate
antiviral immunity on their own and instead cooperate
with numerous other signaling pathways to activate
the full complement of antiviral functions. For example,
MAVS-deficient mice infected with VSV suffer severe
mortality despite a strong systemic type I IFN response
provided by TLR-dependent recognition in pDCs
(Sun et al., 2006). Moreover, fibroblasts lacking Fas-
associated death domain protein (FADD), an important
signaling molecule in the RIG-I and MDA5 pathways,
are unable to curtail VSV replication in vitro, even when
pretreated with recombinant type I IFNs (Balachandran
et al., 2004). Thus, although the paracrine function of
type I IFNs is a very efficient way for infected cells to dis-
seminate an alarm signal, these findings suggest that
IFN-inducible effectors on their own are not sufficient to
confer immunity and highlight the other key roles that
type I IFNs play in coordinating the antiviral response.
Cell-Intrinsic Antiviral Defense: Type I IFNs
and Apoptosis
It is well known that treatment of cells with type I IFNs
sensitizes them to apoptosis upon subsequent viral in-
fection (Stark et al., 1998). The rationale for this response
is fairly simple: because viruses require host cell ma-
chinery to replicate, elimination of an infected cell would
shut down this machinery and thus prevent viral spread.
Many viruses have evolved mechanisms to interfere with
host cell apoptosis, reflecting the importance of this
process in antiviral defense (Seet et al., 2003).
How do interferons sensitize cells to apoptosis? Sev-
eral overlapping mechanisms likely exist. PKR is re-
quired for apoptosis of cells in response to polyI:C
transfection, which activates MDA5 (Balachandran
et al., 2000). Paradoxically, PKR-deficient fibroblasts
are far more sensitive to apoptosis when infected with
VSV; this apoptotic response in PKR-deficient cells is
correlated with an inability to curtail VSV replication
and can be reversed by pretreatment of the cells with
type I IFNs (Balachandran et al., 2000). The tumor
suppressor p53 also may play an important role in virus-
induced apoptosis. p53 is interferon inducible, p53-
deficient cells are defective in VSV-induced apoptosis,
and p53-deficient mice are highly susceptible to in vivo
infection with VSV (Takaoka et al., 2003). It is also possi-
ble that signaling from the cytosolic nucleic acid recep-
tors might cooperate with type I IFN signaling to activate
apoptosis in infected cells. The observation that the
RIG-I and MDA5 signaling adaptor MAVS is localized
to the outer membrane of mitochondria suggests the
interesting possibility that this pathway may interact
with Bcl2 family members, which modulate apoptosis
from the mitochondrial membrane (Seth et al., 2005).
The strong link between type I IFNs and cell-intrinsic
apoptosis may be an important clue to the evolutionary
Review
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brates and not in any other class of organisms. Perhaps
it is because vertebrates are unique in the animal king-
dom in that they use apoptosis as a potent form of
host defense. When would the benefits of apoptosis (re-
moval of an infected cell) outweigh the costs (loss of an
important cell) enough to make it a useful form of de-
fense? Only when tissue renewal can prevent impair-
ment of physiological functions caused by irreplaceable
cell loss. Most cells of adult invertebrate animals are
postmitotic, which would make the deliberate removal
of even a few key cells in invertebrates highly deleteri-
ous. The few examples of renewable tissue in inverte-
brates, such as the tentacles of octopi and starfish and
the segments of earthworms, are clearly secondary ad-
aptations and occur by de novo regeneration instead of
by continuous replacement of individual cells over time.
In contrast, most cells in vertebrate animals are renew-
able and continually replenished throughout adult life.
There are exceptions to this general rule, including cer-
tain postmitotic neuronal populations, and the rate of
cell renewal varies widely among tissues, with epithelial
cells and hepatocytes at the faster end of the spectrum
and tissues like heart muscle at the slower end. It would
be interesting to determine whether a cell’s utilization of
the type I IFN system for apoptosis is directly propor-
tional to its ‘‘renewability.’’ This would imply that a post-
mitotic, irreplaceable neuron would respond to type I
IFNs quite differently than an easily renewable epithelial
cell; even the signaling downstream of the widely
distributed cytosolic nucleic acid sensors might vary
considerably depending on the type of infected cell. A
deeper understanding of this specificity in the type I
IFN system would have important implications for clini-
cal treatment of viruses with cell type-specific tropism.
Interestingly, the other class of organisms that uses
programmed cell death for defense also has renewable
tissues: plants activate a hypersensitivity response to
eliminate host cells surrounding sites of infection and
prevent pathogen spread. Instead of type I IFNs, plants
use inducible production of other types of rapidly diffus-
ing soluble mediators to relay an alarm signal among
their noncirculating cells (Nimchuk et al., 2003).
Non-Cell-Autonomous Roles of Type I IFNs
In addition to cell-intrinsic effects of type I IFNs that con-
fer the antiviral state, the IFN system is linked to a variety
of effector responses of the innate and adaptive immune
systems. One characteristic shared by IFN-regulated ef-
fector responses is that their activation ultimately results
in the elimination of infected cells. Thus, two major
effector cell populations regulated by type I IFNs are
natural killer (NK) cells and cytotoxic T cells (CTLs). In
addition, type I IFNs have been shown to facilitate cross-
presentation by DCs for presentation of viral antigens to
CD8+ T cells (Le Bon et al., 2003). Cytotoxic responses
mediated by NK cells and CTLs are designed to elimi-
nate infected cells, so it appears that a common feature
of IFN activity is the defense against intracellular
infections.
The mechanisms whereby type I IFNs contribute to
NK and CTL responses are diverse and include produc-
tion of chemokines that recruit the cytotoxic cells to the
site of infection and induction of cytokines that posi-tively regulate cytotoxic cell numbers and activities.
For example, type I IFNs induce production of IL-15,
which plays a critical role in proliferation and mainte-
nance of NK cells and memory CD8+ T cells (Nguyen
et al., 2002a; Zhang et al., 1998). IFNs also directly acti-
vate NK cells to enhance their cytotoxic activity (Lee
et al., 2000; Nguyen et al., 2002a).
A number of studies have demonstrated that type I
IFNs also play an essential role in the differentiation
and function of effector CD8+ T cells. Murali-Krishna
and colleagues explored the role of type I IFNs in the
CD8+ T cell response to infection with lymphocyte cho-
riomeningitis virus (LCMV), a well-characterized model
of CD8+ T cell function and memory (Kolumam et al.,
2005). They found that CD8+ T cells lacking the type I
IFN receptor were profoundly impaired in their ability
to expand and differentiate into effector CTLs, demon-
strating that type I IFNs provide a nonredundant costi-
mulatory signal in vivo.
A study by Taniguchi and colleagues suggests a more
context-specific role for type I IFNs in CD8+ T cell differ-
entiation. Knockout mice lacking interferon regulatory
factor 7 (IRF7), a transcription factor required for
TLR9-mediated type I IFN production in pDCs, were un-
able to mount a CD8+ T cell response to protein antigens
delivered with the TLR ligand CpG DNA as an adjuvant
(Honda et al., 2005a). In contrast, CD8+ T cell expansion
and function in IRF7-deficient mice was normal when
TLR2 ligands were used as the adjuvant. Acute deple-
tion of pDCs in wild-type mice gave similar results and
selectively impaired CD8+ T cell responses when protein
antigen was administered with TLR9 ligands but not
when the same antigen was delivered with TLR2 ligands.
TLR2 is expressed by conventional DCs and does not
activate type I IFNs, so it is reasonable that the CD8+ T
cells that emerge after TLR2 activation would not require
IFNs. However, TLR9 can also activate conventional DC
maturation and production of inflammatory cytokines
such as IL-12, yet this conventional DC-derived pathway
is insufficient to compensate for loss of pDC-derived,
TLR9-activated type I IFNs in IRF7-deficient mice. One
interesting question raised by these findings is whether
pDCs are the relevant antigen-presenting cells after pro-
tein and CpG DNA immunization or whether they provide
type I IFNs in trans to CD8+ T cells encountering peptide-
MHC complexes on a different antigen-presenting cell.
Another question with implications for vaccine develop-
ment is whether this selective requirement for pDCs and
type I IFNs revealed with TLR9 ligands extends to the
RNA ligands for TLR7. If so, this would imply that TLR
activation in pDCs drives the differentiation of a special-
ized type of CD8+ effector T cells that is distinct from
those that encounter antigens presented by conven-
tional DCs. Together with the in vivo studies that use
LCMV infection, it now appears that there are at least
two types of CD8+ T cells: those that require type I
IFNs for expansion and function and those that do not.
Thus, vaccines aiming to elicit protective CD8+ T cell
memory against viral infection should target the pDC-
mediated TLR7 and TLR9 response, whereas vaccines
against other pathogens like gram-positive bacteria
should be designed to expand the type I IFN-indepen-
dent subset of CD8+ T cells. Because these two types
of effector CTLs are generated by different pathways,
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378Figure 1. Context-Specific Actions of Type I IFNs
(A) In uninfected cells, type I IFN signaling in the absence of other cues would activate the expression of IFN-inducible genes that make cells more
sensitive to detection and elimination of incoming virus.
(B) Infected cells integrate type I IFN signals with cytosolic nucleic acid recognition to activate cell-intrinsic apoptosis and the expression of li-
gands that allow NK cells and CTLs to distinguish an infected cell that must be eliminated from its uninfected neighbors.
(C) For CD8+ T cells encountering MHC-peptide antigens in the context of viral infection, T cell receptor and costimulatory receptor signaling
cooperates with type I IFNs to drive their clonal expansion and differentiation. This function of type I IFNs is quite different from its usual role
in establishing the antiviral state, which slows host cell metabolism.
(D) In dendritic cells encountering nucleic acid TLR ligands, autocrine or paracrine type I IFNs facilitate crosspresentation of MHC class I pep-
tides derived from endocytosed viral particles or apoptotic, virally infected cells.it is likely that type I IFN-dependent memory CTLs may
not be efficient against a pathogen that does not trigger
type I IFN production; conversely, the IFN-independent
CTLs would be unable to provide protective immunity
to viral infection.
Interestingly, the effect of type I IFNs on CD8+ T cells is
dependent on the stage of CD8+ T cell differentiation.
Whereas type I IFNs limit nonspecific CD8+ T cell expan-
sion in a STAT1-dependent manner, they promote anti-
gen-specific expansion and IFN-gproduction by CTLs in
a STAT4-dependent fashion (Nguyen et al., 2002b).
Thus, the relative abundance of STAT1 and STAT4 in
CD8+ T cells determines the outcome of their exposure
to IFNs. This context-dependent effect of type I IFNs is
characteristic of their activity, which we will discuss in
the next section.
Context-Specific Actions of Type I IFNs
An emerging principle in type I IFN biology is the realiza-
tion that type I IFNs are part of a contextual language
that can mean different things to different cells or even
within the same cell depending on the presence of other
cues. A simplified model that summarizes some of the
contextual meanings of type I IFNs discussed above is
depicted in Figure 1. A cell encountering type I IFNs in
the absence of other cues will activate the classical an-
tiviral state by upregulating expression of interferon-in-
ducible genes (Figure 1A). These genes include nucleic
acid sensors like RIG-I and MDA5; increased abundance
of these sensors would make cells surrounding an in-
fected cell more sensitive to detection of virus. Within
an infected cell, type I IFN signaling can pair with cell-
autonomous detection of viral nucleic acids (Figure 1B).
It is likely that these two pathways collaborate to distin-
guish an infected cell from its uninfected neighbors in at
least two ways. First, these two pathways may synergizeto activate cell-intrinsic apoptosis in infected cells. Sec-
ond, they may result in modulation of cell-surface li-
gands that instruct NK cells and CTLs to kill an infected
cell that cannot commit apoptosis on its own. Impor-
tantly, the type I IFNs in this case need not be autocrine
and could be supplied in trans by pDC-derived systemic
IFNs; however, cell-intrinsic nucleic acid recognition
must be a prerequisite for apoptosis and modulation
of NK and CTL ligands.
Paradoxically, in CD8+ T cells receiving appropriate T
cell receptor and costimulatory signals, type I IFN sig-
naling is essential for the massive expansion and differ-
entiation of virus-specific effector CTLs (Figure 1C). A
similar situation exists in NK cells, where type I IFN
signaling collaborates with activating NK receptors to
enhance NK cell-mediated cytotoxicity. It is understand-
able that virus-specific CTLs would be placed under the
control of cytokines that specifically announce the pres-
ence of virus. But what would happen if the CD8+ T cells
were themselves infected? This model suggests that
cell-intrinsic viral detection would revert infected CD8+
T cells to the state depicted in Figure 1B and implies
that cell-intrinsic nucleic acid detection is dominant
over activation and differentiation cues when paired
with type I IFN signals. This cell-autonomous antiviral
state would arrest the cell cycle, block host cell mRNA
translation, and drive cells to commit apoptosis, thus
preventing the unwanted scenario of infected cells in-
creasing their numbers. Importantly, ‘‘bystander’’ acti-
vation of CD8+ T cells by type I IFNs in the absence of
a TCR and costimulatory signal would revert them to
a conventional antiviral state.
Finally, type I IFN signaling in DCs, when paired with
a TLR signal, would favor crosspresentation of antigens
within the TLR-containing phagosome (Figure 1D). Dur-
ing crosspresentation, viral antigens from infected cells
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I loading machinery. The fact that type I IFNs both facil-
itate this presentation of virus-derived peptides and also
are essential for differentiation of the CD8+ T cells
specific for these crosspresented antigens may provide
a dual safeguard against inappropriate expansion of
non-antigen-specific CTLs.
There is important clinical relevance to the contextual
language of type I IFNs. For example, vaccines designed
to combine a TLR signal with type I IFNs would likely
have a different effect than vaccines that also activate
a cytosolic nucleic acid sensor. Additionally, viruses
are known to target both type I IFN receptor signaling
as well as the signaling machinery that links cytosolic
nucleic acid recognition to activation of type I IFNs
(Foy et al., 2003; Garcia-Sastre and Biron, 2006). Based
on the pairing of these two pathways in infected cells,
therapies that would restore both of these functions
would be far more effective than those that restore either
IFN signaling or nucleic acid detection. In the case
of hepatitis C virus, inhibition of the virus-encoded
NS3/4A protease that cleaves and inactivates MAVS
would reactivate both functions in infected cells (Loo
et al., 2006; Meylan et al., 2005). As we continue to
develop our knowledge of the different pathways that
cooperate with type I IFNs to achieve diverse outcomes,
we will be in a position to better understand the subtle-
ties of this contextual language and use it for therapeutic
benefit.
Conclusions and Perspectives
Several years of remarkable progress have illuminated
the many different points at which type I IFNs are inte-
grated into host defense. With this progress, a number
of basic principles that govern type I IFN function have
emerged. Two general features unite the receptors
that activate production of type I IFNs. First, these re-
ceptors coordinate the immune response against intra-
cellular pathogens, including viruses and probably cyto-
solic bacteria. Second, nucleic acid recognition appears
to underlie most of an organism’s ability to activate type
I IFNs. We can say this with fair certainty for RNA virus
detection based on the recent characterization of the
RIG-I- and MDA5-signaling pathways. Whether the
same principle holds true for recognition of DNA viruses
and intracellular bacteria remains to be seen. If true,
then the source of type I IFNs that play a pathogenic
role in many autoimmune settings must be an aberrant
recognition of self nucleic acids by these sensors,
a cost of this imperfect recognition strategy that detects
pathogen components that are also present in the host
(the role of type I IFNs in autoimmunity will be discussed
in an accompanying review; Banchereau and Pascual,
2006).
The sensors that activate type I IFNs probably have
other important functions as well. This is certainly true
for TLRs expressed by DCs, which are integrated into
a number of key processes including antigen presenta-
tion (and crosspresentation) and inducible expression of
other molecules that initiate the adaptive immune re-
sponse. The cell-intrinsic cytosolic sensors might also
have diverse functions beyond activation of type I inter-
ferons, including induction of apoptosis and modulation
of ligands that flag infected cells for elimination by NKcells and CTLs. An important area of future research
will be the precise elucidation of these IFN-independent
functions and all of the signaling pathways activated by
these receptors.
In conclusion, the pace of recent advances in our un-
derstanding of how type I IFNs operate in immunity sug-
gests that major breakthroughs in vaccine development
and clinical treatment of viral infections are more attain-
able now than ever before. The discovery of many of the
receptors that activate type I IFNs along with the details
of antiviral signaling pathways provides a fertile new
ground for development of strategies to enhance or in-
tercept these responses in the event of pathogen infec-
tion or autoimmunity, respectively.
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